title: A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
abstract: Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride. Remoxipride was evaluated in a low (30 to 90 mg), medium (120 to 240 mg) and a high (300 to 600 mg) dose range and compared with a haloperidol (15 to 45 mg), which was administered to a similar group of patients. The results support the antipsychotic effect of remoxipride, with maximum efficacy occurring at daily doses between 120 mg and 600 mg. Side-effects were more frequent at doses of remoxipride over 300 mg. In all groups, remoxipride caused consistently fewer extrapyramidal side-effects than haloperidol. The antipsychotic effect of remoxipride may be derived from specific blockade of dopamine D2 receptors in the mesolimbic tract. The findings also suggest that remoxipride may have a therapeutic effect on negative symptoms of schizophrenia.
authors.affiliation: Royal Ottawa Hospital, University of Ottawa, Ontario.
authors.forename: Y D
authors.initials: YD
authors.lastname: Lapierre
authors.forename: R
authors.initials: R
authors.lastname: Ancill
authors.forename: G
authors.initials: G
authors.lastname: Awad
authors.forename: D
authors.initials: D
authors.lastname: Bakish
authors.forename: P
authors.initials: P
authors.lastname: Beaudry
authors.forename: D
authors.initials: D
authors.lastname: Bloom
authors.forename: R
authors.initials: R
authors.lastname: Chandrasena
authors.forename: M
authors.initials: M
authors.lastname: Das
authors.forename: C
authors.initials: C
authors.lastname: Durand
authors.forename: D
authors.initials: D
authors.lastname: Elliott
mesh_terms: D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006220:Haloperidol / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D017330:Remoxipride / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D017330:Remoxipride; D006220:Haloperidol